|
|
Treatment With Buspirone in a Patient With Autism
Louis H. McCormick, MD
Arch Fam Med. 1997;6(4):368-370.
References Article references have been provided for searching and linking. Additional reference information may be available in the article PDF.
| |
1. Cook EH. Autism: review of neurochemical investigation. Synapse. 1990;6:292-308.
PUBMED
2. Anderson GM, Horne WC, Chatterjee D, Cohen DJ. The hyperserotonemia of autism. Ann N Y Acad Sci. 1990;600:331-340.
PUBMED
3. Taylor DP, Becker JA, Crane M, Hyslop DR, Riblet LA, Temple DL. Chronic treatment with buspirone reduces type two serotonic binding sites. Soc Neurosci Abstr. 1983;9:435.
4. Vandermaelen CP, Wilderman RC. Iontophoretic and systemic administration of the non-benzodiazepine anxiolytic drug buspirone causes inhibition of serotonergic dorsal raphe neurons in rats. Fed Proc. 1984;43:947.
5. Newton RE, Marunycz JD, Alderdice MT, Napoliello MJ. Review of the sideeffect profile of buspirone. Am J Med. 1986;80(suppl_3B):17S-21S.
6. Realmuto GM, August GJ, Garfinkel BD. Chemical effect of buspirone in autistic children. J Clin Psychopharmacol. 1989;9:122-125.
PUBMED
7. Ratey JJ, Sovner R, Mikkelsen E, Chmielinski HE. Buspirone therapy for maladaptive behavior and anxiety in developmentally disabled persons. J Clin Psychiatry. 1989;50:382-384.
PUBMED
8. McCormick LH, Rizzuto GT, Khuckles HB. A pilot study of buspirone in attentiondeficit hyperactivity disorder. Arch Fam Med. 1994;3:68-70.
FREE FULL TEXT
9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987. 10. Conners CK. Rating scales for use in drug studies with children. Psychopharmacol Bull. 1973;9:24-84.
11. Larson EB, Ellsworth AJ. Oas J. Randomized clinical trials in single patients during a 2-year period. JAMA. 1993;270:2708-2712.
FREE FULL TEXT
12. Edwards DR, Bristol MM. Autism: early identification and management in family practice. Am Fam Physician. 1991;44:1755-1764.
PUBMED
|